International Cancer Prevention Society (ICAPS)

10th International Conference on Lung Cancer Prevention

2 December 2017, Vienna/Austria

 

program


Friday, 2nd December 2016

 

09:00 – 09:05

Greetings and Opening Statements for the 10th ICAPS Conference on Clinical Cancer Prevention

Speaker: ICAPS President & Conference Chair: Powel Brown, Clinical Cancer Prevention, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA

 

 

09:05 – 10:30

 

Session I: Lung Cancer Chemoprevention Studies / New Agents

Chair: Eva Szabo, MD, Lung and Upper Aerodigestive Cancer Research Group, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States

 

Phase II Trial Testing Aspirin for the Prevention of Lung Cancer

Bernardo Bonanni, MD, Division of Cancer Prevention and Genetics, European Institute of Oncology, Milan, Italy

 

 

Developing Iloprost for Prevention of Lung Cancer

York E. Miller, Lung Research, University of Colorado Cancer Center, Denver, Colorado, United States

 

 

Budesonide for Lung Cancer Prevention

Giulia Veronesi, MD, Department of Robotic Thoracic Surgery, Humanitas Research Hospital, Milan, Italy

 

 

Retinoids for the Treatment and Prevention of Lung Cancer

Xi Liu, PhD, MD Anderson Cancer Center, Houston, United States

   

 

 
10:30 – 11:00 Coffee break, Poster set‐up for accepted abstracts

 

 

11:00 – 11.35

 

 

Session II Future Lung Cancer Prevention Trials

Chair: Frank Meyskens, MD, ICAPS Past‐President (1998‐2004), University of California, Irvine, California, United States

 

Plenary Talk: Are We Ready for Phase III Prevention Trials in Lung Cancer?

Eva Szabo, MD, Lung and Upper Aerodigestive Cancer Research Group, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States

 

 

11:35 – 13:00

 

Lunch break

 

   
13:00 – 13:25

Session III Lung Cancer Risk – Tobacco and Beyond

Chair: Mangesh Thorat, MBBS, MS, DNB, ICAPS Strategic Planning & Funding Officer, Queen Mary University of London, London, United Kingdom

 

Developing a Global Approach to Tobacco Control

Pascal Bovet, MD, MPH, Institute of Social and Preventive Medicine, University Hospital of Lausanne, Switzerland

 

 

13:25 – 14:05

Session IV Molecular Lung Cancer Screening and Early Detection

Chair: Leslie Ford, MD, Division of Cancer Prevention, National Cancer Institute, Rockville, Maryland, United States

 

Genomic Classifier to Improve Lung Cancer Detection

Avi Spira, MD, Boston University, Boston, United States

 

Multi‐international Study for Early Detection of Lung Cancer

Sam Hanash, MD, PhD, MD Anderson Cancer Center, Houston, United States

 

 

14:05 – 14:25

 

Coffee break

 

 

14:25 - 15:30

 

Session V Novel Strategies for Smoking Cessation

Chair: Jack Cuzick, PhD, ICAPS Past President (2005‐2013), Queen Mary University of London, London, United Kingdom

 

Vaccines Against the Nicotine Receptor

Peter Burkhard, PhD, University of Connecticut, USA, and Co‐Founder and CEIO, Aplha‐O Peptides AG, Riehen, Switzerland

 

Nicotine Metabolism – Genetic Predictors of Smoking Cessation and Abstinence

Caryn Lerman PhD, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania

 

Advances in Promoting Smoking Cessationr

Paul Cinciripini, PhD, Behavioral Science, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA

 

 

15:30 – 15:50

 

Coffee break

 

 

15:50 – 16:55

 

Session VI Selected Abstract Oral Presentations

Chair:Powel Brown, ICAPS President & Conference Chair, Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

 

Panel‐selected students, fellows and early investigators Focus: Presentation of top‐ranking abstracts

 

 

16:55 – 17:00

Coffee break

 

 

17:00 – 18:00

 

Session VII Panel Discussion and Consensus Statement: Options for Lung Cancer Chemoprevention

Chair:Powel Brown, ICAPS President & Conference Chair, Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; David Carbone, MD, Ohio State University Medical Center, Columbus, Ohio, USA

 

Speakers and Session Chairs

Focus: Open discussion of current options for the prevention of lung cancer to facilitate and enhance the development of a consensus statement

 

18:00

 Close of Day's Events

 

 

Saturday, 3rd December 2016

 

 

Workshop: IASLC Supporting the Implementation of Global CT Screening

 

 

Chair: John Field, UK; James L. Mulshine, USA

 

Objectives:

  1. This IASLC SSAC Workshop will provide an overview of the recent advances in lung cancer screening.
  2. To provide a forum to discuss the pertinent issues around implementation, which will impact on all health services as they move towards implementation.
  3. What can be achieved in the next three years and recommendation for the IASLC Exec as to how they can support leadership in this area of lung cancer.
  4. The consensus from this workshop will be published.

 

09:00 – 09:10

Welcome and Aims of Workshop

 

 

09:10 – 09:50

 

Session I: Integrating Smoking Cessation into Future Lung Cancer CT Screening Programmes ‐ Utilising the ‘Teachable Moment’

 

Personalised Tobacco Cessation in the CT Screening Setting

 

Opportunities to Enhance the Cost Effectiveness of CT screening Through the Integration of Tobacco Cessation

 

Discussion

 

 

09:50 - 11:00

Session II: Radiological Imaging and Work‐Up

 

CT Scan Detected Nodule Management Protocol

Innovative Approaches to Quantitative Imaging Quality Control for Lung Cancer Screening

Opportunities to Advance Lung Cancer Screening Approaches Using Data Registries

Progress in Advancing Lung Cancer Screening Internationally

Discussion

 

 

11:00 - 11:30

Coffee break

 

 

11:30 – 12:30

 

Session III: Integration of Molecular Biomarkers and Utilisation of CT for CHD & COPD

 

Imaging as a Biomarker – and What Is Required From a Molecular Biomarker

ImaLife

Lung CT Screening: Complementary Benefits – CHD & COPD

Discussion

 

12:30 – 13:30

Lunch

13:30 – 15:50

 

Session IV: The Current Global Implementation of CT lung cancer Screening Programmes Outside the USA

 

Update on Low‐dose CT Lung Cancer Screening Implementation in USA

The Current Implementation Plan in Canada

The Shanghai Screening Trial

The Cancer Screening Programs in Urban China

Surgical Status of Screen Detected Lung Cancer – Future Prospective?

Lung Cancer Screening in Australia

Developing Lung Cancer Screening Plans in South America

Annual or Biennial Lung Cancer Screening – What Is the Evidence?

Netherlands & Europe Awaiting the NELSON Publication Prior to Implementation

US National Lung Cancer Round Table

Discussion

 

15:50 - 16:20

Coffee break
Rorschacherstr. 150
CH-9006 St. Gallen/Switzerland
Tel. +41 (0)71 243 00 32
Fax. +41 (0)71 245 68 05